MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelinesMassimo Filippi, Frederik Barkhof, Maria A. Rocca et al.|The Lancet Neurology|2016Cited by 863
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosisMike P. Wattjes, Olga Ciccarelli, Daniel S. Reich et al.|The Lancet Neurology|2021Cited by 646
Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysisLudwig Kappos, Massimo Filippi, David Moeri et al.|The Lancet|1999Cited by 500
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosisAlena Novotná, Jan Mareš, S. Ratcliffe et al.|European Journal of Neurology|2011Cited by 465
Deep gray matter volume loss drives disability worsening in multiple sclerosisArman Eshaghi, Ferrán Prados, Wallace Brownlee et al.|Annals of Neurology|2018Cited by 441